HUP0400620A3 - Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds - Google Patents

Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds

Info

Publication number
HUP0400620A3
HUP0400620A3 HU0400620A HUP0400620A HUP0400620A3 HU P0400620 A3 HUP0400620 A3 HU P0400620A3 HU 0400620 A HU0400620 A HU 0400620A HU P0400620 A HUP0400620 A HU P0400620A HU P0400620 A3 HUP0400620 A3 HU P0400620A3
Authority
HU
Hungary
Prior art keywords
prodrugs
compounds
preparation
amino acids
pharmaceutical compositions
Prior art date
Application number
HU0400620A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01500263A external-priority patent/EP1310480A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0400620A2 publication Critical patent/HUP0400620A2/hu
Publication of HUP0400620A3 publication Critical patent/HUP0400620A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
HU0400620A 2001-01-11 2001-12-14 Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds HUP0400620A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01500007 2001-01-11
EP01500206 2001-08-02
US32978601P 2001-10-16 2001-10-16
EP01500263A EP1310480A1 (en) 2001-11-07 2001-11-07 Prodrugs of excitatory amino acids
PCT/US2001/045866 WO2002055481A1 (en) 2001-01-11 2001-12-21 Prodrugs of excitatory amino acids

Publications (2)

Publication Number Publication Date
HUP0400620A2 HUP0400620A2 (hu) 2004-12-28
HUP0400620A3 true HUP0400620A3 (en) 2012-09-28

Family

ID=27440162

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400620A HUP0400620A3 (en) 2001-01-11 2001-12-14 Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds

Country Status (24)

Country Link
US (1) US7256217B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368304B1 (cg-RX-API-DMAC7.html)
JP (1) JP4064237B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030090622A (cg-RX-API-DMAC7.html)
CN (1) CN1267407C (cg-RX-API-DMAC7.html)
AR (1) AR036007A1 (cg-RX-API-DMAC7.html)
AT (1) ATE356111T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002228737B2 (cg-RX-API-DMAC7.html)
BR (1) BR0116770A (cg-RX-API-DMAC7.html)
CA (1) CA2433667C (cg-RX-API-DMAC7.html)
CZ (1) CZ303490B6 (cg-RX-API-DMAC7.html)
DE (1) DE60127182T2 (cg-RX-API-DMAC7.html)
DZ (1) DZ3461A1 (cg-RX-API-DMAC7.html)
ES (1) ES2282315T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0400620A3 (cg-RX-API-DMAC7.html)
IL (1) IL156364A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006186A (cg-RX-API-DMAC7.html)
NO (1) NO20033166L (cg-RX-API-DMAC7.html)
NZ (1) NZ526050A (cg-RX-API-DMAC7.html)
PE (1) PE20020829A1 (cg-RX-API-DMAC7.html)
PL (1) PL208413B1 (cg-RX-API-DMAC7.html)
SK (1) SK287934B6 (cg-RX-API-DMAC7.html)
SV (1) SV2003000836A (cg-RX-API-DMAC7.html)
WO (1) WO2002055481A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
KR101598679B1 (ko) 2011-06-17 2016-02-29 일라이 릴리 앤드 캄파니 mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
WO2019201842A1 (de) 2018-04-17 2019-10-24 Bayer Aktiengesellschaft Verfahren zur herstellung von estern n-acylierter aminosäuren mit säurelabilen keto-schutzgruppenfunktionen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206915T1 (de) 1994-08-12 2001-11-15 Lilly Co Eli Behandlung von angstzuständen
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
IL118727A (en) 1995-06-29 2003-01-12 Lilly Co Eli (-)-2-spiro-5-hydantoinbicyclo [3.1.0] hexane-6-carboxylic acid, salts thereof and use thereof for the preparation of (+)-(2) aminobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1182105C (zh) 1998-01-28 2004-12-29 大正制药株式会社 含氟氨基酸衍生物
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
WO2002055485A1 (en) 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1423411A2 (en) 2001-07-09 2004-06-02 Eli Lilly And Company Prodrugs of excitatory amino acids
AU2002353845A1 (en) 2001-11-23 2003-06-10 Eli Lilly And Company Prodrugs of excitatory amino acids
AU2002361611A1 (en) 2001-12-21 2003-07-24 Eli Lilly And Company Prodrugs of excitatory amino acids

Also Published As

Publication number Publication date
HUP0400620A2 (hu) 2004-12-28
CN1486298A (zh) 2004-03-31
DE60127182T2 (de) 2007-11-22
NZ526050A (en) 2005-03-24
BR0116770A (pt) 2003-12-23
CN1267407C (zh) 2006-08-02
AU2002228737B2 (en) 2007-01-04
SK8262003A3 (en) 2004-01-08
IL156364A0 (en) 2004-01-04
US20040121962A1 (en) 2004-06-24
CZ20031916A3 (en) 2004-03-17
NO20033166D0 (no) 2003-07-10
ATE356111T1 (de) 2007-03-15
US7256217B2 (en) 2007-08-14
SK287934B6 (sk) 2012-05-03
SV2003000836A (es) 2003-01-13
KR20030090622A (ko) 2003-11-28
JP4064237B2 (ja) 2008-03-19
NO20033166L (no) 2003-09-09
MXPA03006186A (es) 2004-02-13
CA2433667C (en) 2011-06-14
CZ303490B6 (cs) 2012-10-17
CA2433667A1 (en) 2002-07-18
DE60127182D1 (de) 2007-04-19
DZ3461A1 (fr) 2002-07-18
EP1368304B1 (en) 2007-03-07
WO2002055481A8 (en) 2003-10-02
ES2282315T3 (es) 2007-10-16
PL361669A1 (en) 2004-10-04
JP2004524292A (ja) 2004-08-12
PL208413B1 (pl) 2011-04-29
WO2002055481A1 (en) 2002-07-18
AR036007A1 (es) 2004-08-04
EP1368304A1 (en) 2003-12-10
PE20020829A1 (es) 2002-09-21

Similar Documents

Publication Publication Date Title
HUP0401763A3 (en) Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them and process for preparation the compounds
HUP0400998A3 (en) Novel compounds of anti-inflammatory, immunomodulatory and anti-proliferatory effect, process for their preparation and pharmaceutical compositions containing them
HUP0303347A3 (en) Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis polymorphonucleate and mononucleate cells, process for their preparation and pharmaceutical compositions containing them
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
HUP0302499A3 (en) Pharmaceutical compositions of estrogen-cyclodextrin complexes and process for their preparation
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
PL355844A1 (en) Novel pharmaceutical compositions of anti-tubrcular drugs and process for their preparation
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
HUP0303724A3 (en) Chemokine receptors inhibitor bipiperidinyl-derivatives and pharmaceutical compositions containing them and process for preparation of the compounds
HUP0105108A3 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
AU9473601A (en) Stable solid dosage forms of amino acids and processes for producing same
AP2002002575A0 (en) Compounds having hypolupedemic and hypocholestermic activities process for their preparation and pharmaceutical compositions containing them
HUP0401747A3 (en) Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
HUP0204520A3 (en) Pharmaceutical composition containing esmolol and process for its preparation
HUP0302912A3 (en) Betha-thio-amino acids, process for their preparation and pharmaceutical compositions containing them
SG120874A1 (en) Process for the preparation of peptides
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer
HUP0200116A3 (en) Amide compounds for the potentiation of cholinergic activity and pharmaceutical compositions containing them and process for the preparation of the compounds
HUP0200913A3 (en) Isoindoindololone derivatives process for their preparation and pharmaceutical compositions containing them
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
HUP0201024A3 (en) Izoindeindolone compounds, process for their preparation and pharmaceutical compositions containing them
IL156364A0 (en) Prodrugs of excitatory amino acids
HUP0105307A3 (en) Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors and pharmaceutical compositions thereof and process for preparation the compounds
IL162770A0 (en) Process for the preparation methylsteroids of 7

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees